RECK and metabolic dysfunction-associated steatotic liver disease: In detail, published data on the downregulation of RECK expression and liver-related cancer, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), NAFLD progression to NASH and ischemia/reperfusion (I/R) injury have been reviewed, as well as the effects of RECK regulation by inducers.